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Two-thirds of breast tumours are oestrogen-receptor positive and 60–70% of these tumours respond to interventions that reduce
the effects of oestrogen. Until recently, tamoxifen was the drug of choice for the treatment of hormone-responsive early and
advanced breast cancer. However, tamoxifen is associated with increased incidences of endometrial cancer and thromboembolic
disease, and many tumours eventually become resistant to treatment with tamoxifen. Thus, there is a need for alternative therapies
with different mechanisms of action. In postmenopausal women, aromatase inhibitors (AIs) suppress oestrogen levels by inhibiting
oestrogen synthesis via the aromatase enzyme pathway. The third-generation AIs (anastrozole, letrozole and exemestane) are more
potent than the earlier AIs (aminoglutethimide, formestane and fadrozole) with respect to both aromatase inhibition and oestrogen
suppression. While the earlier AIs were unable to show any benefit over megestrol acetate or tamoxifen as second- and first-line
therapy, respectively, in postmenopausal women with advanced breast cancer, third-generation AIs have shown significant benefits in
both settings. Comparison of aromatase inhibition and oestrogen suppression between the third-generation AIs anastrozole and
letrozole showed a small but significantly greater difference in the degree of suppression of oestrone and oestrone sulphate (but not
oestradiol), with letrozole. In an open-label trial, there were no significant differences between letrozole and anastrozole for the
clinical end points of time to progression (primary end point), time to treatment failure, overall survival, clinical benefit, duration of
clinical benefit, time to response, duration of response or objective response rate in patients with confirmed hormone receptor-
positive tumours. Together these data suggest that once a certain threshold of aromatase inhibition is reached, small differences in
oestrogen suppression between the third-generation AIs do not lead to clinically significant differences in overall efficacy.
British Journal of Cancer (2004) 90, 1733–1739. doi:10.1038/sj.bjc.6601731 www.bjcancer.com
Published online 13 April 2004
& 2004 Cancer Research UK
Keywords: anastrozole; aromatase inhibition; oestrogen suppression; potency; clinical efficacy
                                                     
Breast cancer is regarded world wide as a major cause of morbidity
and mortality in both pre- and postmenopausal women, and
currently comprises 18% of all female cancers (McPherson et al,
2000). In the UK, breast cancer accounts for more than 14000
deaths each year (McPherson et al, 2000), while in Europe in 1995
it was responsible for the deaths of 124000 women (Bray et al,
2002). However, between 1988 and 1998 mortality from the disease
fell dramatically among women below the age of 70 years in
Western (but not Eastern) Europe (Levi et al, 2001). Possible
reasons for this improved mortality rate include the introduction
of national breast screening programmes and new better treatment
regimens (Blanks et al, 2000; Levi et al, 2001).
It is recognised that two-thirds of breast tumours are oestrogen-
receptor positive and women who have hormone receptor-positive
tumours are suitable candidates for endocrine therapy (Forbes,
1997). The use of endocrine therapy for the management of the
disease has grown dramatically since the first pioneering report by
Beatson in 1896 of a successful outcome in a premenopausal
woman with breast cancer following ovarian ablation (Beatson,
1896), and many different treatment approaches are now available.
Although significant progress has been made over the past three
decades in terms of both improved efficacy and tolerability of
endocrine treatments for breast cancer, many challenges still lie
ahead for both surgeons and oncologists in the treatment and
management of all stages of the disease.
Until recently, and for more than 30 years, tamoxifen – a
selective oestrogen receptor modulator (SERM) – had been the
drug of choice for the treatment of hormone-responsive early and
advanced breast cancer. However, although tamoxifen is an
effective treatment, it has partial agonist activity. This is associated
with an increase in the incidence of endometrial cancer (Fisher
et al, 1996) and of thromboembolic disease (Jaiyesimi et al, 1995;
Fisher et al, 1996), and limits its use. In addition, most tumours
eventually become resistant to tamoxifen and alternative treat-
ments are required. In recent years, a number of different classes
of endocrine therapy have emerged as suitable alternatives in the
treatment of advanced breast disease. Although several new SERMs
have been developed (e.g. raloxifene), they have not been shown to
produce any clinically relevant effects in the treatment of
tamoxifen-resistant tumours (Johnston, 2001). Thus, there is a
need for new therapies with improved tolerability profiles that are
not cross-resistant with established endocrine therapies such as
tamoxifen. The availability of endocrine agents with different
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lmechanisms of action to tamoxifen, such as the aromatase
inhibitors (AIs), is an important step forward in the search to
provide more efficacious and better-tolerated therapies.
The AIs have been developed for the treatment of women with
breast cancer in whom ovarian function has ceased either due to
the menopause or as a result of ovarian ablation, through
oophorectomy or by ovarian irradiation. They prevent the
formation of oestrogen from androgens in postmenopausal women
through inhibition of the cytochrome P450 enzyme, aromatase,
which catalyses the conversion of androgens to oestrogens in the
fat, liver and muscle cells (Dowsett et al, 1995; Geisler et al, 1996)
and breast tumour tissue itself (Bhatnagar et al, 2001; Geisler et al,
2001). In premenopausal women, the ovaries are the primary site
of oestrogen production and AIs are not able to completely block
ovarian oestrogen synthesis.
Aminoglutethimide was the first AI to become available in the
late 1970s (Wells et al, 1978) and the first to show efficacy as
second-line therapy after tamoxifen in postmenopausal women
with advanced hormone-responsive breast cancer. However, its
toxicity and lack of selectivity for the aromatase enzyme,
necessitating concomitant corticosteroid supplementation (Wells
et al, 1978), prevented it from becoming a more widely used
treatment. Formestane, a steroidal AI, became available in 1993. It
was also effective for treatment of postmenopausal women with
advanced breast cancer, but more selective than aminoglutethi-
mide, and therefore associated with fewer side effects. However, as
a result of extensive first-pass metabolism, formestane cannot be
given orally and has to be administered twice-monthly by
intramuscular injection, leading to reports of local reactions in
up to 17% of patients (Goss et al, 1986).
The newer third-generation AIs, which include the nonsteroidal
agents, anastrozole, letrozole and fadrozole (Japan only) and the
steroidal compound, exemestane (Figure 1), are the most recent
AIs to become available for use in postmenopausal women with
metastatic hormone-responsive breast tumours. These AIs show
increased potency with respect to both aromatase inhibition and
oestrogen suppression compared with the earlier AIs. Small but
statistically significant differences in potency have also been
reported between third-generation AIs (Geisler et al, 2002).
An important question is whether or not these differences in
potency between the third-generation AIs lead to clinically relevant
differences in efficacy and tolerability. This paper reviews current
published data on potency and clinical efficacy to determine if any
such relationship exists.
WHOLE-BODY OESTROGEN SUPPRESSION AND
AROMATASE INHIBITION
Comparison of first- and second- vs third-generation
aromatase inhibitors: oestrogen suppression and
aromatase inhibition
Indirect comparisons of oestrogen suppression by the first- and
second-generation AIs aminoglutethimide, formestane and fadro-
zole and the third-generation AIs anastrozole and exemestane that
were conducted in the same laboratory, have shown that third-
generation AIs are more potent than the earlier AIs (Figure 2).
These studies demonstrated that aminoglutethimide (1000mg once
daily (o.d.)) suppressed oestradiol levels by 75% (MacNeill et al,
1992), while formestane (250mg o.d.) and fadrozole (1mg twice
daily) suppressed oestradiol by approximately 59% (Dowsett et al,
1990; Lnning et al, 1991; Jones et al, 1992). Anastrozole (1mg
o.d.) and exemestane (10mg o.d.) showed similar activities to each
other (84 vs 85%, respectively) and were more potent than
aminoglutethimide, formestane and fadrozole (Geisler et al, 1996;
Johannessen et al, 1997). Similar differences between the agents
were observed with respect to aromatase inhibition (Figure 2). An
unrelated study comparing anastrozole (1mg o.d.) with letrozole
(2.5mg o.d.) (Geisler et al, 2002) showed that anastrozole was as
potent as letrozole in terms of oestradiol suppression (84.9 vs
87.8%, respectively, P¼0.1088), although the difference in
aromatase inhibition between anastrozole and letrozole was
significant (97.3 vs 499.1%, respectively, P¼0.0022) (Figure 2)
(Geisler et al, 2002).
Direct comparison of third-generation aromatase
inhibitors, anastrozole and letrozole: oestrogen
suppression
The study in which anastrozole was directly compared with
letrozole (Geisler et al, 2002) was a small-scale, randomised,
double-blind, cross-over trial. In all, 12 postmenopausal women
with oestrogen receptor-positive metastatic tumours suitable for
treatment with AIs were enroled into the study. Six patients
received 6 weeks of anastrozole (1mg o.d.) followed by 6 weeks of
letrozole (2.5mg o.d.), while the other six received 6 weeks of
letrozole followed by 6 weeks of anastrozole. Compared with
anastrozole, letrozole showed small but significantly increased
suppression of oestrone and oestradiol sulphate concentrations
(Figure 3), but as discussed above, there was no difference in
suppression of oestradiol (Geisler et al, 2002).
CLINICAL EFFICACY
Comparison of the third-generation aromatase inhibitors
with megestrol acetate and aminoglutethimide as second-
line therapy for advanced breast cancer
Several Phase III studies have compared the efficacy of the third-
generation AIs in postmenopausal women with advanced breast
cancer who have progressed on tamoxifen, vs the previous
standard treatments in this setting, megestrol acetate or amino-
glutethimide (Table 1).
The efficacy of anastrozole (1mg or 10mg od) compared with
megestrol acetate [40mg four times daily (qd)] has been assessed
in two trials, one European (Jonat et al, 1996) and one North
American (Buzdar et al, 1997), prospectively planned for
combined analysis (Buzdar et al, 1996a). The results summarized
in Table 1 are of the combined analysis.
After a median follow-up of 6 months, time to progression
(TTP) and objective response (OR¼completeþpartial response)
rate did not differ significantly for the 1 and 10mg anastrozole
groups compared with the megestrol acetate group (Table 1). The
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Figure 1 Structures of anastrozole, letrozole, exemestane and fadrozole.
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mately one-third of patients in each treatment group benefited
from therapy (Buzdar et al, 1996a). After 31 months of follow-up
(Buzdar et al, 1998), anastrozole (1mg) demonstrated a significant
survival advantage over megestrol acetate (Table 1). There was no
significant difference for overall survival between anastrozole
10mg and megestrol acetate, although numerical advantages have
been shown in favour of anastrozole 10mg, with longer median
time to death (25.5 vs 22.5 months for anastrozole 10mg and
megestrol acetate, respectively; P¼0.09) and lower death rate at 2
years (45.4 vs 53.7%, respectively). Therefore, while there was no
advantage for the higher dose of anastrozole, the data are
consistent with, and supportive, of the findings observed with
the clinically approved 1mg dose.
Two trials have investigated the efficacy of letrozole (2.5 or
0.5mg o.d.) vs megestrol acetate 40mg q.d. (Dombernowsky et al,
1998; Chaudri and Trunet, 1999; Buzdar et al, 2001) (Table 1).
Results of the European trial (Dombernowsky et al, 1998) showed
the OR rate was significantly higher for patients receiving letrozole
2.5mg than for letrozole 0.5mg (P¼0.004) or megestrol acetate
(P¼0.04) (24, 13 and 16%, respectively). Letrozole 2.5mg was
superior to letrozole 0.5mg for TTP (P¼0.02), but not compared
with megestrol acetate. At a 51-month follow-up analysis for the
letrozole 2.5mg arm (Chaudri and Trunet, 1999), letrozole did not
show significant survival benefit over megestrol acetate (Table 1).
In the US trial (Buzdar et al, 2001), no significant differences were
reported for TTP (Table 1) or OR rate and, contrary to the first
trial, the efficacy of letrozole was not dose related. No significant
survival benefit was seen for letrozole vs megestrol acetate
(Table 1). It has been speculated that these contradictory findings
may be the result of an imbalance of prognostic factors in favour of
megestrol acetate in the latter trial (Wischnewsky et al, 2002).
In a further open-label trial, letrozole (2.5 and 0.5mg o.d.) was
compared with aminoglutethimide (250mg, twice daily) (Gersha-
novich et al, 1998) (Table 1). The higher dose of letrozole (2.5mg
daily) was superior to aminoglutethimide for overall survival
(P¼0.002), TTP (Cox regression analysis, P¼0.008) and TTF (Cox
regression analysis, P¼0.003). There were no significant differ-
ences in OR seen in patients receiving letrozole 2.5mg, letrozole
0.5mg or aminoglutethimide. Letrozole 2.5mg showed a signifi-
cant advantage over the letrozole 0.5mg dose for survival
(P¼0.04), but there was not a significant dose–response effect
for letrozole in terms of TTP, in line with the results from the US
trial of letrozole vs megestrol acetate (Buzdar et al, 2001). In
addition, a trial that assessed the impact of letrozole 2.5 and 0.5mg
o.d. on peripheral aromatisation of androstenedione to oestrone
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aromatisation (Dowsett et al, 1995). All patients on the lower
dose showed 497% inhibition and on the higher dose showed
498% inhibition. There was no evidence of any difference
between letrozole 2.5 and 0.5mg in suppression of oestrone (80.8
and 82.0%, respectively) and oestradiol (68.1 and 84.1%,
respectively), but no formal statistical analysis was performed.
These results draw into question the dose–response effect seen for
letrozole in the European trial of letrozole vs megestrol acetate
(Dombernowsky et al, 1998; Chaudri and Trunet, 1999).
A large, randomised, double-blind trial has compared exemes-
tane (25mg o.d.) with megestrol acetate (40mg q.d.) (Kaufmann
et al, 2000). There was significant improvement in TTP for
exemestane compared with megestrol acetate (Table 1), while OR
rate was not significantly different between groups. Exemestane
also showed significant improvement in overall survival compared
with megestrol acetate (Table 1), although this was after a shorter
median follow-up (11.4 months) compared with the anastrozole
and letrozole studies.
Overall, although there have been some differences in outcome
and the end points at which significant benefits have been
observed, the newer-generation AIs have all proven more effective
and better tolerated than the progestogen megestrol acetate, and
letrozole has demonstrated superior efficacy to aminoglutethimide,
for the second-line treatment of patients with advanced breast
cancer failing on tamoxifen. As a result, third-generation AIs are
now established as the standard treatment in this patient
population. In contrast, the second-generation AIs formestane
and fadrozole have shown no significant efficacy benefits over
megestrol acetate in patients progressing on tamoxifen (Buzdar
et al, 1996b; Thu ¨rlimann et al, 1997).
Comparison of the third-generation aromatase inhibitors
with tamoxifen as first-line therapy for advanced breast
cancer
Results of the Phase III studies assessing the efficacy of the third-
generation AIs vs tamoxifen as first-line therapy in postmenopau-
Table 1 Overview of efficacy results from Phase III trials of second-line treatment of advanced breast cancer. Aromatase inhibitors vs megestrol acetate
and aminoglutethimide in patients who have failed on tamoxifen (Buzdar et al, 1996a,b; 1998; Dombernowsky et al, 1998; Gershanovich et al, 1998; Chaudri
and Trunet, 1999; Kaufmann et al, 2000; Buzdar et al, 2001)
European & US
combined analysis European trial US trial International trial International trial
A MA L MA L MA L AG E MA
Dose 1mg o.d.
(n¼263)
40mg q.d.
(n¼253)
0.5mg o.d.
(n¼188)
2.5mg o.d.
(n¼174)
40mg q.d.
(n¼189)
0.5mg o.d.
(n¼202)
2.5mg o.d.
(n¼199)
40mg q.d.
(n¼201)
0.5mg o.d.
(n¼192)
2.5mg o.d.
(n¼185)
250mg b.d.
(n¼178)
2.5mg o.d.
(n¼366)
40mg
q.d.
(n¼403)
Median
follow-up
(months)
31 33 37 20 11
Median TTP
(months)
4.8 4.6 5.1 5.6 5.5 6.0 3.0 6.0 3.3 3.4 3.2 4.7 3.8
ns ns 0.5mg vs MA, P¼0.044 2.5mg vs AG, P¼0.008 P¼0.037
Median
survival
(months)
26.7 22.5 21.5
a 25.3
a 21.5
a 33 29 26 21 28 20 NR 28.4
Po0.025 ns ns 2.5mg vs AG, P¼0.002 P¼0.039
aSurvival data from an extended 51-month follow-up analysis. A¼anastrozole; MA¼megestrol acetate; L¼letrozole; AG¼aminoglutethimide; E¼exemestane; o.d.¼once
daily; q.d.¼four times daily; b.d.¼twice daily; TTP¼time to disease progression; NR¼not reached; ns¼nonsignificant.
Table 2 Nonsteroidal aromatase inhibitors vs tamoxifen as first-line treatment
TARGET study (Bonneterre
et al, 2000)
N American study
(Nabholtz et al, 2000)
Combined study
(Bonneterre et al, 2000)
Letrozole study (Mouridsen
et al, 2001)
ATATATLT
n¼340 n¼328 n¼171 n¼182 n¼511 n¼510 n¼453 n¼454
TTP overall population
(months)
8.2 8.3 11.1 5.6 8.5 7.0 9.4 6.0
NS P¼0.005 NS P¼0.0001
TTP HR+ve subgroup
(months)
8.9 7.8 NA 10.7 6.4 9.2 5.8
NA P¼0.022 P¼0.0001
CB (%) 56.2 55.5 59.1 45.6 57.1 52.0 49.0 38.0
NA P¼0.0098 P¼0.1129 P¼0.001
OR (%) 32.9 32.9 21.0 17.0 29.0 27.1 30.0 20.0
NS NA NS P¼0.0006
HR+ve (%) 45 89 60 66
A¼anastrozole; T¼tamoxifen; L¼letrozole; TTP¼time to disease progression; NA¼not available; HR+ve¼hormone receptor-positive; CB¼clinical benefit;
OR¼objective response; NS¼not significant.
Potency vs clinical efficacy of aromatase inhibitors
R Sainsbury
1736
British Journal of Cancer (2004) 90(9), 1733–1739 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lsal women with advanced breast cancer are summarised in Table 2.
These data indicate the superiority of the third-generation
nonsteroidal AIs compared with tamoxifen in this patient
population.
The efficacy of anastrozole vs tamoxifen was assessed in two
Phase III trials, one European (the Tamoxifen and Arimidex
Randomized Group Efficacy and Tolerability (TARGET) trial)
(Bonneterre et al, 2000) and one North American (Nabholtz et al,
2000), which were identical in design and prospectively planned
for combined analysis. Anastrozole was shown to be at least as
effective as tamoxifen as first-line treatment of postmenopausal
women with advanced breast cancer, although some variation in
data was observed between the two individual Phase III trials
(depending upon the proportion of patients whose tumours were
hormone receptor-positive). In the North American trial, TTP and
clinical benefit (CB) rates were significantly better for anastrozole
compared with tamoxifen (Table 2). In the TARGET trial,
anastrozole was shown to be equivalent to tamoxifen in terms of
TTP and OR rates (Table 2). The difference in outcome was
attributed to differences in the proportion of patients with
confirmed hormone receptor-positive tumours (89 vs 45% for
the North American and TARGET trials, respectively). Analysis of
the subgroup that comprised only patients with hormone receptor-
positive tumours (45%) in the TARGET trial showed a similar
separation of the Kaplan–Meier curves to that seen in the overall
population in the North American trial (in which 89% of patients
had hormone receptor-positive tumours). The combined analysis
of the two trials also showed anastrozole to be superior to
tamoxifen for TTP in patients with hormone-sensitive advanced
breast cancer (Table 2) (Bonneterre et al, 2001).
In a single Phase III study in postmenopausal women with
advanced breast cancer, letrozole was also found to be superior to
tamoxifen for several efficacy end points (Mouridsen et al, 2001).
Time to progression, CB and OR rates were significantly better for
letrozole (Table 2). In addition, TTF was significantly longer for
letrozole compared with tamoxifen (median TTF: 9.2 vs 5.7
months, respectively, P¼0.0001).
Although no data from Phase III trials of exemestane are
currently available, the results of a Phase II trial of exemestane
(25mg o.d., n¼31) vs tamoxifen (20mg o.d., n¼32) are
promising (Paridaens et al, 2000). Median TTP was 8.9 vs 5.2
months for exemestane and tamoxifen, respectively, and OR rates
were 42 vs 16%, respectively. A Phase III trial is ongoing.
In contrast to the third-generation AIs, the second-generation
agents fadrozole and formestane have not shown any significant
efficacy benefits over tamoxifen in the advanced disease setting
(Perez Carrion et al, 1994; Falkson and Falkson, 1996).
Direct comparison of the third-generation aromatase
inhibitors: anastrozole vs letrozole as second-line therapy
Anastrozole (1mg o.d.) and letrozole (2.5mg o.d.) were compared
as second-line treatment for advanced breast cancer with hormone
receptor-positive or unknown receptor status in postmenopausal
women who had progressed on tamoxifen in a multicentre, open-
label, randomised Phase III–IV study (Rose et al, 2002). The
primary end point was TTP and secondary end points included OR
rate, response duration, duration of clinical benefit, TTF, time to
response and overall survival (OS).
A total of 713 postmenopausal patients were randomly allocated
to either letrozole 2.5mg o.d. (n¼356) or anastrozole 1mg o.d.
(n¼357). Patient characteristics were well balanced between
treatment groups (Rose et al, 2002). A total of 48% of patients
had hormone receptor-positive tumours (Rose et al, 2002).
Efficacy end points are shown in Table 3. In the overall population,
anastrozole was similar to letrozole for TTP (P¼0.920), TTF
(P¼0.761) and OS (P¼0.624). The only differences between
anastrozole and letrozole were for OR rate in both the overall
population and the unknown receptor status subgroup, which were
higher in the letrozole vs the anastrozole group (overall popula-
tion: 19.1 vs 12.3%, odds ratio¼1.70, P¼0.014; unknown receptor
status subgroup: 20.8 vs 8.4%, respectively) (Rose et al, 2002).
However, in patients with confirmed hormone receptor-positive
tumours there was no difference in OR between anastrozole and
letrozole (28/167 [16.8%] vs 30/173 [17.3%], respectively). As the
overall population included patients with unknown receptor
status, it is possible that in this unknown receptor group there
was a greater number of patients randomised to letrozole who had
hormone receptor-positive tumours and who would respond to
letrozole. If this was the case, it could account for the higher OR
rate with letrozole in the overall population. Presently, the number
of patients with unknown receptor status in each group has not
been published. Furthermore, no results for TTP in the hormone
receptor-positive population have been published to date, so the
relative efficacy of anastrozole and letrozole for this end point is
uncertain.
SUMMARY
The AIs have been developed for treatment of breast cancer in
postmenopausal women with hormone receptor-positive tumours
and it is important that they are used to treat this group of
patients. Third-generation AIs (anastrozole, letrozole and exemes-
tane) show improved potency with respect to suppression of
aromatase activity and circulating oestrogen levels compared with
the older-generation AIs (aminoglutethimide, formestane and
fadrozole) (Dowsett et al, 1990; Lnning et al, 1991; Jones et al,
1992; MacNeill et al, 1992; Geisler et al, 1996). This increased
potency correlates with improved clinical efficacy of the third-
generation AIs relative to the older drugs. Thus, while formestane
and fadrozole, which inhibit aromatase by o85%, have shown no
benefits over megestrol acetate (Buzdar et al, 1996b; Thu ¨rlimann
et al, 1997) or tamoxifen (Perez Carrion et al, 1994; Falkson and
Falkson, 1996) as second- and first-line therapy, respectively,
third-generation AIs, which inhibit aromatase activity by 496%,
show significant clinical efficacy benefits over these standard
second- and first-line comparators (Buzdar et al, 1996a, 1998,
2001; Dombernowsky et al, 1998; Bonneterre et al, 2000; Kaufmann
et al, 2000; Nabholtz et al, 2000; Bonneterre et al, 2001; Mouridsen
et al, 2001).
In contrast, direct comparison of the third-generation AIs
anastrozole and letrozole has shown that although letrozole
suppresses aromatase activity, oestrone and oestrone sulphate
levels to a greater degree than anastrozole, these differences in
Table 3 Efficacy data in patients randomised to anastrozole or letrozole
(Rose et al, 2002)
ITT population
Anastrozole
(n¼357)
Letrozole
(n¼356) P-value
Median TTP
a (months) 5.7 5.7 0.920
Median TTF (months) 5.6 5.6 0.761
Median OS (months) 20.3 22.0 0.624
Objective response (%)
Total population 12.3 19.1 0.014
HR+ve subgroup 16.8 17.3 NA
Unknown receptor
status subgroup
8.4 20.8 NA
aTTP: primary end point; ITT¼intention to treat; TTP¼time to disease progression;
TTF¼time to treatment failure; OS¼overall survival.
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efficacy of these agents for the second-line treatment of hormone-
sensitive advanced breast cancer (Rose et al, 2002).
The fact that these marginal differences in potency between
anastrozole and letrozole do not appear to produce clinically
relevant differences in efficacy suggests that there may be a
threshold effect for aromatase inhibition/oestrogen suppression
beyond which no further improvements in clinical efficacy can be
gained. Since the potency of formestane, aminoglutethimide and
fadrozole fall below this threshold, the third-generation AIs show
clinical efficacy benefits relative to these older agents. Of note,
however, is that although clinical efficacy may be unaffected by
small differences in potency, this does not preclude the fact that
small differences in oestrogen suppression may lead to differences
in side-effect profiles, especially with respect to cardiovascular end
points or effects on bone mineral density, and this is more likely to
become apparent during longer-term treatment as these drugs
move into the adjuvant setting.
CONCLUSION
The third-generation AIs are more potent inhibitors of the
aromatase enzyme and cause greater oestrogen suppression than
older agents such as aminoglutethimide, fadrozole and formestane.
This is linked to an increase in the clinical efficacy of the third-
generation AIs relative to the previous standard comparators in
both the second- and first-line settings. In contrast, small changes
in potency between anastrozole and letrozole are not associated
with clinically relevant differences in their efficacy in the treatment
of hormone-sensitive advanced breast cancer, suggesting the
existence of a threshold of oestrogen suppression above which
no further improvements in clinical efficacy can be gained.
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